The Present and FutureState-of-the-Art ReviewAre PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field?
State-of-the-Art Review
Under an Elsevier user license
open archive
Key Words
cholesterol
lipids
low-density lipoprotein
Abbreviations and Acronyms
CHD
coronary heart disease
FH
familial hypercholesterolemia
HDL
high-density lipoprotein
LDL-C
low-density lipoprotein cholesterol
LDL-R
low-density lipoprotein receptor
MoAb
monoclonal antibody
PCSK9
proprotein convertase subtilisin/kexin type 9
SC
subcutaneous
SOC
standard of care
Cited by (0)
Dr. Giugliano has received grant support from Merck and AstraZeneca; grant support and personal fees from Amgen and Daiichi-Sankyo; and personal fees from Bristol-Myers Squibb, CVS Caremark, Pfizer, and Sanofi outside the submitted work. Dr. Sabatine has received grant support from Abbott Laboratories, Accumetrics, Critical Diagnostics, Daiichi-Sankyo, Eisai, Genzyme, Nanosphere, Roche Diagnostics, Takeda, and Gilead; grant support and personal fees from Amgen, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Intarcia, Merck, and Sanofi; and personal fees from Aegerion, Alnylam, Cubist, MyoKardia, Pfizer, Quest Diagnostics, Vertex, Zeus Scientific, and CVS Caremark outside of the submitted work.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.